As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Savara Inc. The largest reported stake is Growth Equity Opportunities 17, LLC's, at 12%. 14 filings are on record since July 8, 2025 (Schedule 13D/A, November 14, 2025).
Sell to companies like Savara Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: TCG Crossover GP I, LLC · Percent: 6.1% · SCHEDULE 13G/A
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Nantahala Capital Management, LLC · Percent: 3.61% · SCHEDULE 13G/A
- · Holder: Frazier Life Sciences Public Fund, L.P. · Percent: 4.1% · SCHEDULE 13G/A
- · Holder: Dapice Joshua J. · Percent: 6.9% · SCHEDULE 13G/A
Savara Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-08. 6 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Growth Equity Opportunities 17, LLC | 12% | 24,471,264 | SCHEDULE 13D/A, 2025-11-14 | 2025-11-12 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 20,881,288 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| 6.9% | 15,000,000 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 | |
| Deerfield Mgmt, L.P. | 6.74% | 13,569,000 | SCHEDULE 13G, 2025-11-05 | 2025-10-30 |
| TCG Crossover GP I, LLC | 6.1% | 12,362,205 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| BlackRock, Inc. | 5.4% | 10,957,322 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Frazier Life Sciences Public Fund, L.P. | 4.1% | 8,343,048 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Nantahala Capital Management, LLC | 3.61% | 7,344,783 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Vestal Point Capital, LP | 2.3% | 4,015,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Savara Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Savara Inc. and the records around it.
Savara Inc. elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Watch Savara Inc.
Get an email when Savara Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Savara Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Savara Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Savara Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Growth Equity Opportunities 17, LLC
GEO acquired the GEO Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, GEO and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Venrock Healthcare Capital Partners III, L.P. | 5.2% | SCHEDULE 13G |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 3.9% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 4.8% | SCHEDULE 13G/A |
| 2025-11-05 | Deerfield Mgmt, L.P. | 6.74% | SCHEDULE 13G |
| 2025-11-14 | Vestal Point Capital, LP | 2.3% | SCHEDULE 13G/A |
| 2025-11-14 | Growth Equity Opportunities 17, LLC | 12% | SCHEDULE 13D/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 5.08% | SCHEDULE 13G |
| 2025-11-14 | Venrock Healthcare Capital Partners III, L.P. | 7.3% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-02-05 | Dapice Joshua J. | 6.9% | SCHEDULE 13G/A |
| 2026-02-13 | Nantahala Capital Management, LLC | 3.61% | SCHEDULE 13G/A |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 4.1% | SCHEDULE 13G/A |
| 2026-02-17 | TCG Crossover GP I, LLC | 6.1% | SCHEDULE 13G/A |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Savara Inc.
Who owns Savara Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Savara Inc.: Growth Equity Opportunities 17, LLC (12%, Schedule 13D/A, filed 2025-11-14), Venrock Healthcare Capital Partners III, L.P. (9.9%, Schedule 13G/A, filed 2026-02-17), Dapice Joshua J. (6.9%, Schedule 13G/A, filed 2026-02-05), Deerfield Mgmt, L.P. (6.74%, Schedule 13G, filed 2025-11-05) and TCG Crossover GP I, LLC (6.1%, Schedule 13G/A, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of Savara Inc.?
By the share each holder's latest filing reports, the largest holders of Savara Inc. on this page are Growth Equity Opportunities 17, LLC (12%), Venrock Healthcare Capital Partners III, L.P. (9.9%) and Dapice Joshua J. (6.9%).
When did Growth Equity Opportunities 17, LLC buy into Savara Inc.?
The filings give report dates, not purchase dates. The earliest filing from Growth Equity Opportunities 17, LLC on this page is the Schedule 13D/A, filed 2025-11-14, reporting 12%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Savara Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 8, 2026 | Leadership change: Robert Lutz appointed, Chief Financial and Operating Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Savara Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.